《公司業績》復星醫藥(02196.HK)去年純利47.35億元人幣升29% 派末期息56分人幣
復星醫藥(02196.HK)公佈截至去年12月底止全年業績,營業額388.58億元人民幣(下同),按年升28.8%。純利47.35億元,按年升29.3%;每股盈利1.85元。派每股末期息56分,上年同期派43分。
公司指製藥業務實現營業收入287.72億元按年增長32.30%;實現分部業績29.64億元按年增31.03%;實現分部利潤26.3億元,剔除奧鴻藥業商譽減值等影響因素後,分部利潤同口徑增長22.04%。
就復必泰(mRNA新冠疫苗)相關進進展,集團獲授權在中國大陸及港澳臺地區獨家開發、商業化基於mRNA技術平臺研發的復必泰,2021年3月納入港澳地區政府接種計劃,2021年9月在中國臺灣地區開展接種。截至今年2月末,復必泰於港澳臺地區已累計接種超過2,000萬劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.